Indefinite Delivery Contract 75D30123D15812
Award Date
12/31/22
Last Date to Order
2/28/24
Federal Agency
CDC Pittsburgh
Awardee
Sanofi Pasteur Inc.
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Pricing Type
Firm Fixed Price
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Multiple
Primary Consortia Member
Not listed
Similar IDVs
The Department of Health and Human Services Centers for Disease Control and Prevention awarded a multiple award indefinite delivery contract to Seqirus USA Inc. for adult flu vaccines for 2023-2024. The potential value of the contract is $146,103,060. Orders may be placed through February 28, 2024. The contract aims to procure adult flu vaccines to support the CDC's efforts in disease prevention. As the leading public health agency in the United States, the CDC works to control and prevent...
The Indefinite Delivery Contract awarded by the Department of Health and Human Services Centers for Disease Control and Prevention Pittsburgh provides adult flu vaccines for the 2023-2024 period. Glaxosmithkline, LLC was awarded a multiple award contract with a potential value of $13.9 million to deliver flu vaccines through February 2028 under associated task orders or price lists. The solicitation aimed to procure adult flu vaccines to support the Centers for Disease Control and Prevention's...
This Indefinite Delivery Contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC) to Sanofi Pasteur Inc. to provide adult flu vaccines for the 2024-2025 season. The contract has a ceiling value of $64,529,958.50 and a period of performance through February 28, 2025. As the prime contractor, Sanofi Pasteur Inc. will leverage its pharmaceutical manufacturing and distribution capabilities to efficiently fulfill CDC's requirements for seasonal influenza vaccines to...
This single-award Indefinite Delivery Contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC) to Sanofi Pasteur Inc. to provide adult influenza vaccines for the 2022-2023 flu season. The contract has a ceiling value of $65,825,903.80 and a period of performance from the date of award on December 31, 2021 through February 28, 2023. The original solicitation sought proposals for IDIQ contracts to supply a minimum of 100 doses and a maximum of 20 million doses of...
The Centers for Disease Control and Prevention (CDC), National Center for Immunization and Respiratory Diseases (NCIRD), awarded a multiple-award Indefinite Delivery Contract to Sanofi Pasteur Inc. to purchase 12 standard adult vaccines. The $42.2 million contract has a one-year period of performance from July 1, 2022 to June 30, 2023 and does not have any set-aside designation. The solicitation required offerors to provide minimum and maximum order quantities ranging from 100 to 1,000,000 doses...
The Centers for Disease Control and Prevention awarded a multiple-award indefinite delivery contract to Sanofi Pasteur Inc. to procure adult vaccines. With a potential value of $37.2 million, this vehicle provides for the delivery of various vaccine products and services over its one-year ordering period through June 2022. The contract supports the CDC's adult immunization programs by establishing competitive pricing for items like influenza, pneumococcal, tetanus-diphtheria-acellular pertussis,...
The Centers for Disease Control and Prevention (CDC) has awarded a 5-year, multiple-award Indefinite Delivery Contract (IDC) to Sanofi Pasteur Inc. for the purchase of various adult vaccines. The contract has a ceiling value of $54,975,837.60 and covers the period from July 1, 2024 to June 30, 2025, with the possibility of subsequent option years. As the prime contractor, Sanofi Pasteur Inc. will provide a range of vaccines including Hepatitis A, Hepatitis B, Hepatitis A&B combination,...
Sanofi Pasteur Inc. was awarded a single-award indefinite delivery contract by the Department of Health and Human Services Centers for Disease Control and Prevention potentially valued at $64 million. The contract provides for the delivery of seasonal influenza vaccines to support public health programs as outlined in Section 317(j) of the Public Health Service Act. Performance will occur at the prime contractor's manufacturing facility in Swiftwater, Pennsylvania or other locations as needed to...
This federal contract IDV award from the Centers for Disease Control and Prevention (CDC) to Sanofi Pasteur Inc. is for the supply of 2025-2026 pediatric flu vaccines. The $70.18M multiple award contract has a period of performance through February 2026. As the prime contractor, Sanofi Pasteur will leverage its pharmaceutical manufacturing and distribution capabilities to fulfill task orders for pediatric influenza vaccines in support of the CDC's public health mission. The contract was...
The Centers for Disease Control and Prevention awarded an indefinite delivery contract to Glaxosmithkline, LLC for adult influenza vaccines. The contract has a potential value of $13.41 million to supply a minimum of 100 doses and maximum of 20 million doses of inactivated influenza vaccine for individuals aged 19 years and older through February 28, 2023. Vaccines must be licensed by the FDA and manufactured in compliance with cGMP regulations. Delivery locations include CDC distribution...